Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752804 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL25845775 | 0.80 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2DDB1 | |
| SCHEMBL5069921 | 0.78 | USP2 (0.37) | USP2SMN1; SMN2HPGDEPHX2DDB1 | |
| SCHEMBL240646 | 0.78 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL13661298 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2DDB1 | |
| SCHEMBL1086226 | 0.77 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL15742971 | 0.75 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2DDB1 | |
| SCHEMBL154164 | 0.75 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2DDB1 | |
| SCHEMBL25169698 | 0.75 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2EPHX1 | |
| Hydrochloric Acid SCHEMBL17714540 | 0.74 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7109340-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | BRD4, TP53, HCCS | USP2 4394/4885SMN1; SMN2 2815/4885HPGD 1060/4885 |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | BRD4, TP53, HCCS | USP2 4492/4885SMN1; SMN2 2879/4885HPGD 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.